SCEMBLIX▼ (asciminib) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.1
The below content is for healthcare professionals in Great Britain only. If you require information for Northern Ireland please refer to the Northern Ireland prescribing information.
Mechanism of action (MOA)
SCEMBLIX® (asciminib) is the first and only STAMP inhibitor2–4
Learn how the unique MOA of SCEMBLIX enhances its specificity in treating CML.2
SCEMBLIX targets a different site on BCR-ABL1 – the myristoyl pocket2–4
VIDEO
In people who do not have CML, the myristoyl pocket is occupied by the N-terminal portion of ABL1, maintaining the protein in an inactive conformation.5,6
In BCR-ABL1, the myristoyl pocket is vacant, activating the kinase.5,6
SCEMBLIX is a first-in-class STAMP inhibitor. Binding specifically to the myristoyl pocket, it potently inactivates BCR-ABL1 via allosteric inhibition.2
With its unique MOA, SCEMBLIX offers a different approach for treating CML.5–7
SCEMBLIX demonstrated superior efficacy and a favourable safety profile vs bosutinib at Week 242
ATP, adenosine triphosphate; CI, confidence interval; CML, chronic myeloid leukaemia; CP, chronic phase; MMR, major molecular response; MOA, mechanism of action; Ph + CML, Philadelphia chromosome-positive chronic myeloid leukaemia; STAMP, specifically targeting the ABL1 myristoyl pocket; TKI, tyrosine kinase inhibitor.
For further information please refer to the Summary of Product Characteristics.
References:
SCEMBLIX (asciminib) Summary of Product Characteristics.
Réa D, et al. Blood 2021;138(21):2031–2041.
Redaelli S, et al. J Clin Oncol 2009;27(3):469–471.
Schoepfer J, et al. J Med Chem 2018;61(18):8120–8135.
Hughes TP, et al. N Engl J Med 2019;381(24):2315–2326.
Manley PW, et al. Leuk Res 2020;98:106458.
Iacob RE, et al. PLoS One 2011;6(1):e15929.
UK | October 2024 | 444805
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.